Early human ADME using microdoses and microtracers: bioanalytical considerations. - Wikidata - wikimedia - TriplyDB

Early human ADME using microdoses and microtracers: bioanalytical considerations.

Early human ADME using microdoses and microtracers: bioanalytical considerations.

http://www.wikidata.org/entity/Q37810234

about

Human in Vivo Pharmacokinetics of [(14)C]Dibenzo[def,p]chrysene by Accelerator Mass Spectrometry Following Oral Microdosing Opportunities in low-level radiocarbon microtracing: applications and new technology Quantifying exploratory low dose compounds in humans with AMS.AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration.LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays.Bioanalytical aspects of clinical mass balance studies in oncology.Accelerator MS: its role as a frontline bioanalytical technique.Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.Selected scientific topics of the 11th International Isotope Symposium on the Synthesis and Applications of Isotopes and Isotopically Labeled Compounds.An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808.

P2860

Q28651691-26983D02-DC28-444F-BE93-91E0C914A84F Q28817904-2DB16B2D-5282-4052-885B-EF49026A82D8 Q34708648-B773C40C-7449-4E93-8151-60A58A73863F Q37845381-34881643-4171-4FC2-8A01-08A7B9E7CFE4 Q37923935-B328519F-6C85-42EA-907B-8444B7156498 Q37963912-C83660D4-ABED-4AE8-BDBE-E43E3AF46603 Q37970117-8B776857-3075-4B2B-BD44-6F744B37A641 Q38557519-41245DA5-A240-40BD-B38D-BA684299902A Q53099174-1FB98523-A186-484B-A4ED-4DEA8EC8A568 Q53495828-BDCDAEF9-97A6-4DEB-A024-1C1C0C0B2893

P2860

Early human ADME using microdoses and microtracers: bioanalytical considerations.

http://www.wikidata.org/entity/Q37810234

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@en

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@nl

type

label

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@en

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@nl

prefLabel

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@en

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@nl

P1433

Q37810234-B6AEDC72-26FC-451D-8E8D-54E2748C62E7

P1476

Q37810234-90D3F69E-0E4F-41A9-8C42-512770F3FB25

P2093

Q37810234-1A60D354-36F7-4721-8C62-C21DC5AD2C2A

Q37810234-8005608E-925F-42BE-9ADE-A6357741C950

Q37810234-B9290DC1-4E82-4C54-B516-A24ADADCC75A

Q37810234-BB1162D7-5A92-4D71-8747-883C55F08EFE

Q37810234-D01260C3-699D-4BF5-92E8-6EB1B574B051

Q37810234-D4390E28-3422-45CD-B1F8-C6DEBE22A19C

P2860

Q37810234-064D96BB-F689-4997-BBE7-C8888A1B4FAD

Q37810234-10304F9F-C5F5-4325-9777-55DDE80C5E4F

Q37810234-11ED7A1F-6398-42DD-9F61-4CEC6FEE72DC

Q37810234-197DDC29-A23D-4ADE-9197-2251F3C0751D

Q37810234-24E4ABE1-B61E-4D1E-8F2A-667823A08757

Q37810234-25FCAC28-C841-43D1-BFBB-D086C5910394

Q37810234-33BE6148-36FB-44CE-B6CB-A30386E7DF04

Q37810234-48A91FDE-355C-4990-B60C-5B89740696EA

Q37810234-56E5E1A6-666E-4191-B03B-7A83C06D94F8

Q37810234-59CF06FD-C2EE-4BD1-9FA6-0CEF6F5F2368

P304

Q37810234-5C49370A-CE6A-49D1-B1C6-564F721B3EC6

P31

Q37810234-28DE704D-8E83-4036-AEBB-7E65A8597C83

P356

Q37810234-CDC2BB81-1F00-417B-909A-E2B6FCA8F112

P433

Q37810234-8C41A09E-5B45-4EBB-860B-C830C36F2E72

P478

Q37810234-95DA22AF-8CDD-4217-9408-7B0A039082CA

P577

Q37810234-F16A8E96-7257-410C-9562-9F42964C5706

P5875

Q37810234-377942E4-8161-43CC-B84C-721332456C5E

P698

Q37810234-DF2DF36C-4BA6-4CEC-A6B0-8A485E078240

P356

P1433

P1476

Early human ADME using microdoses and microtracers: bioanalytical considerations.

@en

P2093

Bradly D Keck

http://www.w3.org/2001/XMLSchema#string

Jason A Giacomo

http://www.w3.org/2001/XMLSchema#string

John S Vogel

http://www.w3.org/2001/XMLSchema#string

Peter N Lohstroh

http://www.w3.org/2001/XMLSchema#string

Stephen R Dueker

http://www.w3.org/2001/XMLSchema#string

T Vuong Le

http://www.w3.org/2001/XMLSchema#string

P2860

Analytical validation of accelerator mass spectrometry for pharmaceutical development

An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.

The use of accelerator mass spectrometry to obtain early human ADME/PK data.

What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.

The use of isotopes in the determination of absolute bioavailability of drugs in humans.

Physiologically-based pharmacokinetic simulation modelling.

Drug metabolites in safety testing.

Role of metabolism in drug-induced idiosyncratic hepatotoxicity.

Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.

A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.

P304

441-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/BIO.10.8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47810648

http://www.w3.org/2001/XMLSchema#string

P698

21083254

http://www.w3.org/2001/XMLSchema#string